press release

May 5, 2017

- Results Presented at American Society of Hematology (ASH) Meeting Demonstrate up to 57% AT Knockdown in Initial Multi Dose Cohorts of Hemophilia Subjects and Show Preliminary Clinical Evidence for Potency and Durability of RNAi Therapeutics at Microgram/kg (mcg/kg) Doses Subcutaneous Dose Administration of ALN AT3 Found to be Well Tolerated in Healthy Volunteers and Initial Cohorts ...

press release

May 5, 2017

- By End of 2020, Company Expects to Achieve Profile with 3 Marketed Products, 10 RNAi Therapeutic Clinical Programs Including 4 in Late Stages Across 3 Strategic Therapeutic Areas (STArs) Provides Goals and Guidance for 2015, Exceeding its "Alnylam 5x15" Guidance Established in 2011 and Further Updated in 2014 Increases Guidance to End 2014 with Approximately $880 Million ...

press release

May 5, 2017

- Expands Efforts on Pipeline Development and Commercialization in Genetic Medicine, Cardio Metabolic Disease, and Hepatic Infectious Disease STArs Announces Updated Guidance to File Clinical Trial Application for ALN AS1, an Investigational RNAi Therapeutic for Hepatic Porphyrias, by End 2014 Selects Potent Development Candidate for ALN HBV, Showing Up to 3.9 Log10 Knockdown of Hepatitis Surface Antigen ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the Investors section of the company's website, www.alnylam.com. Alnylam management and key opinion leaders will discuss the latest progress as well as plans for the future ...

press release

May 5, 2017

- Reported Six Month Clinical Data from Phase 2 Open Label Extension (OLE) Study with Patisiran, Showing Tolerability, Sustained Transthyretin (TTR) Knockdown, and Promising Initial Evidence for Stabilization of Neuropathy Progression Completed Phase 2 Enrollment and Initiated Phase 2 OLE Study with Revusiran (ALN TTRsc), and Successfully Completed Non Clinical Chronic Toxicology Studies to Enable Start ...

press release

May 5, 2017

- Results Show a Mean 0.95 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7) at Six Months, Comparing Favorably with Historical Data Sets in FAP Showing Rapid Increase in Neuropathy Progression Patisiran Also Achieved Sustained Knockdown of Serum Transthyretin (TTR) of Up to 90% for Over Nine Months, and was Generally Well Tolerated in Patients Treated ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the expansion of its management team with the appointments of Karen Anderson as Senior Vice President, Chief Human Resources Officer; Laurie Keating as Senior Vice President, General Counsel, and Secretary; and Marko Kozul, M.D., as Vice President, ...

press release

May 5, 2017

- Achieved Positive Initial Results in Ongoing Phase 2 Open Label Extension (OLE) Study with Patisiran, Showing Sustained Clinical Activity with Transthyretin (TTR) Knockdown at an 80% Target Level and Tolerability with Extended Dosing Reported Initial Positive Top Line Data from Phase 1 Clinical Trial with ALN AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and ...

press release

May 5, 2017

- New ALN HBV Program Stems from Alnylam's Acquisition of Sirna Therapeutics from Merck Alnylam Expects to Nominate ALN HBV Development Candidate (DC) with Enhanced Stabilization Chemistry (ESC) GalNAc Conjugate Delivery Platform by End of 2014; File Investigational New Drug Application (IND) around Year End 2015 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), ...

press release

May 5, 2017

- Formed Transformational Alliance with Genzyme for RNAi Therapeutics as Genetic Medicines; Acquired Merck RNAi Assets, Including Sirna Therapeutics Subsidiary Achieved Positive Initial Results from Phase 2 Open Label Extension (OLE) Study with Patisiran, Showing Sustained Clinical Activity with Transthyretin (TTR) Knockdown at an 80% Target Level and Tolerability with Extended Dosing Initiated Phase 1 Study ...